MedTrace Logo

A Study Evaluating the Role of Oral Antibiotics in an Aim to Eradicate Carrier State of Carbapenem- Resistant Klebsiella Pneumonia (KPC).

NCT01266499 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2017-04-28

No results posted yet for this study

Summary

Klebsiella pneumonia, inhabitant of the digestive tract, is a frequent nosocomial pathogen. It is currently the fourth most common cause of pneumonia and fifth most common cause of bacteremia in intensive care patients (1-3).

The aim of the present randomized controlled trial is to assess the efficacy of non-absorbable oral antibiotics in the eradication of the KPC carrier state.

Conditions

  • Klebsiella Pneumoniae Carbapenemase Resistant Associated Bacteremia or Pneumonia

Interventions

DRUG

Colistin (Polymyxin E) 100mg x 4/d

Colistin (Polymyxin E) 100mg x 4/d

DRUG

both medications

PO Garamycin 80mg x 4/d +PO Colistin (Polymyxin E) 100mg x 4/d

DRUG

will not receive PO treatment

will not receive PO treatment - will receive plecebo treatment

DRUG

PO Garamycin 80mg x 4/d

PO Garamycin 80mg x 4/d

Sponsors & Collaborators

  • Rambam Health Care Campus

    lead OTHER

Principal Investigators

  • Tsila Zuckerman, DR · rambam mc

  • ILANA OREN, Dr · Site Sub Investigator

  • Jacob M Rowe, Prof · Site Sub-Investigator

  • RENATO FINKELSTEIN, Prof · Site Sub-Investigator

  • Norberto Krivoy, Prof · Site Sub-Investigator

  • HANA Shprecher, Dr · Site Sub-Investigator

  • Noam Benyamini, Dr · Site Sub-Investigator

  • Salim Hadad, Dr · Site Sub-Investigator

  • Ami Neuberger, Dr · Site Sub-Investigator

  • Eyal Braun, Dr · Site Sub-Investigator

  • Ayelet Raz, Dr · Site Sub-Investigator

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2011-01-31
Completion
2012-01-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01266499 on ClinicalTrials.gov